Krystal Biotech rises on upbeat Q4 results

Krystal Biotech

26/02/2024 14:07

** Shares of gene therapy developer Krystal Biotech  KRYS.O 
rise 13.4% to $126.26 premarket
    ** Co reports Q4 net product revenue of $42.14 mln from
sales of gene therapy Vyjuvek, beating analysts' estimates of
$28.61 mln - LSEG data
    ** Co posts smaller-than-expected Q4 loss of 30 cents per
share vs analysts' estimates of loss of 39 cents
    ** The U.S. FDA approved KRYS's Vyjuvek in May 2023 to treat
 patients with a rare genetic skin disorder called dystrophic
epidermolysis bullosa
    ** As of Dec. 31, 2023 co had cash, cash equivalents and
investments totaling $594.10 mln 
    ** Stock has risen 42.3% in the last 12 months

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))